Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX15 Pexidartinib
D11271 Pexidartinib hydrochloride (JAN/USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, CSF1R, KIT, FLT3
Pexidartinib
D11271 Pexidartinib hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02960 Pexidartinib
D11271 Pexidartinib hydrochloride
DG02924 UGT substrate
DG03182 UGT1A4 substrate
DG02960 Pexidartinib
D11271 Pexidartinib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
KIT (CD117)
D11271 Pexidartinib hydrochloride (JAN/USAN) <US>
FLT3* (CD135) [HSA_VAR:2322v2]
D11271 Pexidartinib hydrochloride (JAN/USAN) <US>
Cytokines and receptors
Cytokine receptors
CSF and other factor receptors
CSF1R (FMS, CD115)
D11271 Pexidartinib hydrochloride (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11271
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11271
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11271
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02960 Pexidartinib
DG02924 UGT substrate
DG03182 UGT1A4 substrate
DG02960 Pexidartinib